Intellectual Property India Publishes Patent Application for 'Crystalline Forms Of An Azetidine Parp1 Inhibitor' Filed by Xinthera, Inc; and Gilead Sciences, Inc.

MUMBAI, India, Nov. 21 -- Intellectual Property India has published a patent application (202517098876 A) filed by Xinthera, Inc; and Gilead Sciences, Inc., Foster City, U.S.A., on Oct. 14, for 'crystalline forms of an azetidine parp1 inhibitor.'

Inventor(s) include Liu, Jing; Reddy, Jayachandra P; Shi, Bing; and Navis, Kathleen E.

The application for the patent was published on Nov. 21, under issue no. 47/2025.

According to the abstract released by the Intellectual Property India: "Described herein are crystalline forms of 5-(((2R,3S)-1-((7-chloro-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl)-2-methylazetidin-3-yl)oxy)-N-cyclopropylpicolinamide (Compound 1), or a pharmaceutically acceptable salt or solvate thereof. Compound 1."

The patent application was internationally filed on Mar. 22, 2024, under International application No.PCT/US2024/021201.

Disclaimer: Curated by HT Syndication.